Patricia Inácio, PhD, science writer —

Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.

Articles by Patricia Inácio

Amolyt Pharma Raises Funding to Help Develop Eneboparatide

Amolyt Pharma has raised €130 million (roughly $138 million) to support the clinical development of eneboparatide, previously AZP-3601, the company’s experimental therapy for hypoparathyroidism. The funding will be used in Phase 3 testing of the treatment and will also help develop AZP-3813 for acromegaly, which occurs when…

Risk of Hypoparathyroidism Seen After Lymph Node Removal

Central lymph node dissection, or the removal of lymph nodes in the neck, increases the risk of both temporary and permanent post-surgical hypoparathyroidism in people with thyroid cancer who undergo surgery to remove the thyroid gland, a 10-year French study reports Also, lateral lymph node dissection along with total…

Ascendis Seeks EMA Approval of TransCon PTH for Adults in EU

Ascendis Pharma is seeking approval of its treatment candidate TransCon PTH for adults with hypoparathyroidism in the European Union, the company has announced. The request, submitted as a marketing authorization application (MAA) to the European Medicines Agency (EMA), follows a similar application submitted in September to the U.S.

AZP-3601 Treatment Still Showing Positive Results in Phase 2 Trial

Daily treatment with AZP-3601, Amolyt Pharma’s investigational therapy for hypoparathyroidism, was well tolerated and allowed patients to discontinue standard supplement treatment, early data from a Phase 2a trial show. The treatment also rapidly normalized 24-hour urine calcium levels and improved bone health. The findings, from a first group of…

Forteo Safely Treats 4-Month-Old With Severe Hypoparathyroidism

Six months of treatment with Forteo (teriparatide) — a lab-made parathyroid hormone fragment approved for osteoporosis — safely led to calcium and phosphate control in a 4-month old girl with severe hypoparathyroidism, a case report found. These findings highlight the potential of this off-label medication to treat infants with…